PA
TVTX icon

Profund Advisors’s Travere Therapeutics TVTX Stock Holding History

Profund Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.02M Buy
67,918
+5,314
+8% +$159K 0.07% 202
2025
Q4 		$2.39M Buy
62,604
+42,366
+209% +$1.38M 0.07% 181
2025
Q3 		$484K Sell
20,238
-6,015
-23% -$113K 0.02% 526
2025
Q2 		$389K Sell
26,253
-4,025
-13% -$66.7K 0.01% 556
2025
Q1 		$543K Sell
30,278
-3,803
-11% -$77.2K 0.02% 444
2024
Q4 		$594K Buy
34,081
+15,181
+80% +$269K 0.02% 429
2024
Q3 		$264K Sell
18,900
-14,936
-44% -$156K 0.01% 873
2024
Q2 		$278K Sell
33,836
-57,898
-63% -$390K 0.01% 764
2024
Q1 		$707K Buy
91,734
+22,247
+32% +$188K 0.03% 459
2023
Q4 		$625K Buy
69,487
+8,504
+14% +$61.9K 0.03% 448
2023
Q3 		$545K Sell
60,983
-28,947
-32% -$408K 0.03% 444
2023
Q2 		$1.38M Buy
89,930
+29,401
+49% +$535K 0.07% 234
2023
Q1 		$1.36M Buy
+60,529
New +$1.29M 0.08% 207

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Profund Advisors's TVTX Position: Q1 2026 in Review

Profund Advisors increased its Travere Therapeutics (TVTX) stake by 8.5% in Q1 2026, buying an estimated $159K and bringing the position to 67,918 shares worth $2.02M. The position accounts for 0.07% of the portfolio, ranked #202.

Profund Advisors first reported a position in TVTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $2.39M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Profund Advisors held 67,918 shares of Travere Therapeutics worth $2.02M as of Q1 2026.
  • Profund Advisors bought 5,314 Travere Therapeutics shares in Q1 2026, an estimated $159K.
  • Travere Therapeutics made up 0.07% of Profund Advisors's portfolio in Q1 2026, its #202 holding.
  • Profund Advisors first reported a position in Travere Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Profund Advisors's Travere Therapeutics position peaked at $2.39M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.